Centaurus Financial’s Alzamend Neuro ALZN Stock Holding History

Centaurus Financial’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9	Closed	-$5K	–	744
2023 Q1	$5K	Hold	9	–	–	﹤0.01%	895
2022 Q4	$7K	Buy	+9	New	+$13K	﹤0.01%	835

Other funds holding ALZN

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

IIC

Integrated Investment Consultants Bloomfield Hills, Michigan $471M AUM 20.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Centaurus Financial's ALZN Position: Q2 2023 in Review

Centaurus Financial sold out of Alzamend Neuro (ALZN) in Q2 2023, closing a stake of 9 shares — an estimated $5K sold.

Centaurus Financial first reported a position in ALZN in Q4 2022 and held it in 2 quarters. The position peaked at $7K in Q4 2022. 20 funds tracked by Wall St. Rank hold ALZN as of Q2 2023.

Centaurus Financial reported no remaining Alzamend Neuro position as of Q2 2023 after selling out during the quarter.
Centaurus Financial sold 9 Alzamend Neuro shares in Q2 2023, an estimated $5K.
Centaurus Financial first reported a position in Alzamend Neuro in Q4 2022 and held it in 2 quarters.
Centaurus Financial's Alzamend Neuro position peaked at $7K in Q4 2022.
20 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2023.

Based on Centaurus Financial's 13F filing for Q2 2023, filed 15 Aug 2023.